Among them, the endometrial cancer, apoptosis, EGFR tyrosine kinase inhibitor resistance, and proteoglycans in the cancer signaling pathway map showed that the PI3K-AKT and RAS-RAF-MEK-ERK (ERK) signaling pathways may play a crucial role in the treatment of EC with DXP (Figure 5). This evidence concerns the gene AKT1 and cancer.